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Results:
n % 10 Year LR free
RT + TAM 98 100 ± 0
RT only 110 93 ± 3
TAM only 107 93 ± 3
Neither 96 82 ± 4
Entry was also allowed to 2-way randomisation for units which
had opted to give RT or TAM to all their cases. Analysis by ran-
domisation then allowed RT versus no RTwith both arms includ-
ing some cases receiving TAM by elective choice of Unit (or) TAM
versus no TAM, both including some cases receiving elective RT.
Results:
n % 10 Year
LR free
% 15 Year
LR free
W-G p
RT 571 97 ± 1 93 ± 1 20.5 <0.000
No RT 568 88 ± 2 86 ± 2
TAM 213 96 ± 2 92 ± 4 12.3 <0.000
No TAM 217 87 ± 3 83 ± 3
Analysis by treatment received confirms that results from ran-
domisation (intention to treat).
Survival overall (all cases) is 91 ± 1% at 10 years.
Conclusion:
1. Omission of any adjuvant therapy led to a recurrence rate of
1.8% per annum. This was reduced by the use of either TAM
only or RT only.
2. Use of both TAM and RT produced no LR’s.
doi:10.1016/j.ejcsup.2010.06.048
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Objectives: To assess whether in older women with ‘low risk’
axillary node negative breast cancer (T0–2, N0, M0) treated by
breast conserving surgery and adjuvant endocrine therapy the
omission of post-operative radiotherapy affects quality of life
and is cost-effective.
Design: Randomised controlled multicentre trial.
Participants: Patients (255) with follow up to 5 years from the
end of recruitment.
Interventions: Whole breast radiotherapy (40–50 Gy) or no
breast radiotherapy.
Main outcome measures: Quality of life, anxiety and depression,
cost effectiveness.
Results: No difference in overall quality of life or anxiety and
depression was found. However, in the subscales of the EORTC
QLQ C30 and BR23 questionnaires, there were significantly higher
levels of insomnia within the non-irradiated group. By contrast,
the irradiated patients reported higher levels of breast symptoms,
and social function was slower to recover. The mean Quality
Adjusted Life Years were similar in the two arms with marginally
higher levels in the radiotherapy arm. The additional cost of pro-
viding radiotherapy was £2128 per patient. Local recurrence rates
at 5 years were 6% (95% CI 0–12%) in the non-irradiated group and
0% in the irradiated group.
Conclusion: Breast radiotherapy is tolerated well by most older
breast cancer patients without impairing their overall health
related quality of life (HRQOL). Concerns about HRQOL should
not be a primary consideration when deciding whether or not
to recommend postoperative radiotherapy after breast conserving
surgery and adjuvant endocrine therapy. The ‘no radiotherapy
option’ is cost effective in the short term.
doi:10.1016/j.ejcsup.2010.06.049
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Background: The Cambridge Breast IMRT Trial demonstrated
that improving dose distribution using IMRT leads to significant
reduction in telangiectasia at comparatively early follow-up.
The secondary aim was to elucidate the influence of patient-
related and surgical factors on late toxicity and cosmesis.
Method: The influence of such factors on late toxicity assessed
using photographic, clinical and patient-reported endpoints at 2
years following radiotherapy was analysed in 1014 patients.
Results: Patients with a moderate or poor baseline surgical cos-
mesis had an increased risk of moderate or poor overall cosmesis
(odds ratio (OR) = 38.19; 95% CI 21.9–66.7; p < 0.0005), and of devel-
oping any clinically assessed breast shrinkage (OR = 4.96; 95% CI
3.67–6.71, p < 0.0005) and induration (OR = 2.78; 95% CI 1.92–4.01,
p < 0.0005) at 2 years. Increased breast volume was significantly
associated with the development of several late toxicity end-
points (p < 0.0005). Current smokers had an increased risk of
developing pigmentation (OR = 2.09, 95% CI 1.23–3.54; p = 0.006).
Post-operative infection requiring antibiotics was associated with
increased risk of telangiectasia (OR = 3.39, 95% CI 1.94–5.91;
p < 0.0005) and breast oversensitivity (OR = 1.78, 95% CI 1.27–
2.49; p = 0.001).
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Conclusions: Baseline post-surgery, pre-radiotherapy cosmesis
is an important determinant of overall cosmesis at 2 years after
radiotherapy. An important component of breast induration and
shrinkage is actually due to surgery rather than radiotherapy. Lar-
ger breast volume, baseline surgical cosmesis, post-operative
infection and smoking influence late radiotherapy toxicity. Modi-
fication of preventable risk factors such as post-operative infec-
tion and smoking may limit the development of late toxicity.
doi:10.1016/j.ejcsup.2010.06.050
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Background: After breast conserving surgery, 90% of recurrent
cancer occurs within the index quadrant. Hence, restricting radi-
ation therapy to the immediate area around the tumour bed after
removal of the primary tumour may be adequate (Vaidya JS et al.
Br J Cancer 1996;74:820–4).
Materials and methods: Using the technique of partial breast
irradiation developed at UCL (Vaidya JS, Baum M, Tobias JS,
et al. Ann Oncol 2001;12:1075–80) we launched the international
TARGIT A randomized controlled trial in March 2000 comparing
the policies of TARGIT versus standard whole breast external
beam radiotherapy (EBRT) after breast conserving surgery with
local recurrence as the main outcome measure (www.thelan-
cet.com/protocol-reviews/99PRT-47). Accrual from 28 interna-
tional centers reached 2232 in April 2010, with 80% power to
detect a difference in relapse rate of 2.5% (the non-inferiority
margin).
Results: Patient demographic and tumour characteristics are as
follows: mean age 63 years (IQR 57–69), mean tumour size 12 mm
(IQR 9–18 mm), N stage 17% +ve. We intend to present the
unblinded data with an analysis of safety and efficacy.
Conclusions: If this analysis shows non-inferiority, then a clin-
ically significant difference in early local recurrence between
TARGIT and EBRT remains unlikely, making single session partial
breast irradiation with TARGITa plausible new standard of care in
the near future.
doi:10.1016/j.ejcsup.2010.06.051
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Background: The Clinic was established in 1973. Over the last
decade, it has evolved into a combined surgical/oncology facility
supported by dedicated breast care nurses. Also, surgery, with
integral axillary staging, and adjuvant radiotherapy (RT) and sys-
temic therapy have become standard for most patients though
non-operative treatments (e.g. primary endocrine therapy (PET))
are used in others based on multi-disciplinary assessment in
the Clinic. This study aimed to compare the clinical outcome
across these periods.
Methods: Over 36 years (1973–2009), 1708 women P70 years
with early operable primary breast cancer were managed in the
Clinic according to a single set of clinical guidelines at any time
point. Analysis was carried out based on retrospective review
and continued update of patient records.
Results: As at 50-month median follow-up (maximum = 261):
1973–1999 2000–2009
N 917 791
Treatment N (%) N (%)
Surgery 392 (42.7) 446 (56.4)
PET 510 (55.6) 324 (41.0)
Primary RT 9 (1.0) 12 (1.5)
No treatment 6 (0.7) 9 (1.1)
Adjuvant endocrine
therapya
124 (31.7) 247 (55.5)
Adjuvant RTa 15 (6.3) 155 (38.4)
Outcome (% per annum) p-value
Local recurrencea 2.2 0.5 <0.000
Regional recurrencea 1.8 0.4 <0.000
Contralateral cancer 0.7 0.4 0.091
Metastasis 2.9 1.9 <0.002
5-year breast cancer
specific survival
80% 90% <0.000
5-year overall survival 56% 68% <0.000
a Surgery group only.
Conclusion: In this recent decade, while surgery became the
predominant treatment, a significant proportion of patients
(40%) had non-operative therapies, selection of which was
based on assessment in the Clinic. This management approach
appears to produce excellent clinical outcome, which is signifi-
cantly better than earlier period.
doi:10.1016/j.ejcsup.2010.06.052
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